Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Humacyte (NASDAQ:HUMA) Stock, Analyst Ratings, Price Targets, Forecasts
Humacyte Inc has a consensus price target of $13 based on the ratings of 9 analysts. The high is $25 issued by D. Boral Capital on November 11, 2024. The low is $3 issued by Piper Sandler on November 10, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and D. Boral Capital on November 18, 2024, November 13, 2024, and November 11, 2024, respectively. With an average price target of $16.33 between HC Wainwright & Co., HC Wainwright & Co., and D. Boral Capital, there's an implied 267.04% upside for Humacyte Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
D. Boral Capital
EF Hutton
TD Cowen
BTIG
1calculated from analyst ratings
Analyst Ratings for Humacyte
Data brought to you by Benzinga APIs
FAQ
What is the target price for Humacyte (HUMA) stock?
The latest price target for Humacyte (NASDAQ:HUMA) was reported by HC Wainwright & Co. on November 18, 2024. The analyst firm set a price target for $12.00 expecting HUMA to rise to within 12 months (a possible 169.66% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Humacyte (HUMA)?
The latest analyst rating for Humacyte (NASDAQ:HUMA) was provided by HC Wainwright & Co., and Humacyte reiterated their buy rating.
When was the last upgrade for Humacyte (HUMA)?
There is no last upgrade for Humacyte
When was the last downgrade for Humacyte (HUMA)?
There is no last downgrade for Humacyte.
When is the next analyst rating going to be posted or updated for Humacyte (HUMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Humacyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Humacyte was filed on November 18, 2024 so you should expect the next rating to be made available sometime around November 18, 2025.
Is the Analyst Rating Humacyte (HUMA) correct?
While ratings are subjective and will change, the latest Humacyte (HUMA) rating was a reiterated with a price target of $12.00 to $12.00. The current price Humacyte (HUMA) is trading at is $4.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.